Reata Pharmaceuticals Announces Presentations Highlighting Clinical Data for Bardoxolone and Disease Education Data on Alport syndrome

Reata Pharmaceuticals Announcements

Reata Pharmaceuticals (RETA) announced that the abstracts highlighting clinical data for bardoxolone methyl (“bardoxolone”) and disease education data on Alport syndrome will be presented at the American Society of Nephrology Kidney Week 2021 being held virtually from November 4 – 7, 2021.

The abstracts for the oral and poster presentations are listed below and are available on the conference website at

Oral Presentation: 

Abstract Title: Integrated Efficacy and Safety of Bardoxolone Methyl in Chronic Kidney Disease  
Presenter: Laura Mariani, MD, Department of Internal Medicine, Division of Nephrology, University of Michigan, Ann Arbor, Michigan, USA 

Session: OR2102. Findings from Landmark Trials, Other Kidney Trials, and Observational Studies 

Abstract Publication: FR-OR54

Leave a Reply